Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

The giant Israeli generics firm extols Cephalon's R&D but the deal's real value may be more nuanced: a combination of cost synergies, late-stage pipeline assets, and expansion of Teva's mix of branded products in anticipation of upcoming challenges in both the branded and generics businesses.

You may also be interested in...



Mesoblast/Teva May Have Shorter Path To Market In Chronic Heart Failure

Now studying stem-cell candidate MPC-150-IM in two 600-patient Phase III trials in advanced heart failure, the partners could complete the Phase III program more quickly and less expensively.

Teva Shoots For Top Three In Pain And Respiratory

Teva’s new management has homed in on pain and respiratory disease as two core therapeutic areas. During the firm’s second quarter earnings call, CEO Erez Vigodman gave a sneak peek at his comprehensive portfolio review.

On The Respiratory Horizon: A Wave Of Biologics For Asthma

Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.

Related Content

Topics

UsernamePublicRestriction

Register

PS072305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel